Episode
ER-Positive, HER2-Positive Metastatic Breast Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy
- Published
- Apr 14, 2026
- Duration seconds
- 3479
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/oncology-today-with-dr-neil-love-1004241/episodes/er-positive-her2-positive-metastatic-breast-cancer-what-clinicians-want-to-know-about-first-line-and-maintenance-therapy/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241/er-positive-her2-positive-metastatic-breast-cancer-what-clinicians-want-to-know-about-first-line-and-maintenance-therapy.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Dr Virginia F Borges from the University of Colorado Anschutz Medical Campus in Aurora and Dr Ian E Krop from Yale Cancer Center in New Haven, Connecticut, review clinical research data and best practices guiding the selection of first-line and maintenance therapy for patients with ER-positive, HER2-positive metastatic breast cancer. CME information and select publications here .